biostudies-literatureBarth DAAustrian Science Fund FWF840207https://www.ebi.ac.uk/biostudies/studies/S-EPMC9010871biostudies-literatureUnknown13<h4>Background</h4>Immune checkpoint inhibitors (ICIs) have revolutionized systemic anti-tumor treatments across different types of cancer. Nevertheless, predictive biomarkers regarding treatment response are not routinely established yet. Apart from T-lymphocytes, the humoral immunity of B-lymphocytes is studied to a substantially lesser extent in the respective setting. Thus, the aim of this study was to evaluate peripheral blood B-cell subtypes as potential predictors of ICI treatment response.<h4>Methods</h4>Thirty-nine cancer patients receiving ICI therapy were included into this prospective single-center cohort study. All had a first blood draw at the date before treatment initiation and a second at the time of first response evaluation (after 8-12 weeks). Seven different B-cell subtFrontiers in immunologyPatterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.PMC9010871W 1226DK-MCD W1226Hertha-Firnberg Grant T1112-BPosch FAhyai SASzkandera JAbsenger GSpiegelberg JABauernhofer TPichler MSmolle MAGerger ABarth DAJost PJStradner MHRiedl JMHutterer GCMadl TKargl JStanzer SKlec CfalsePatterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.<h4>Background</h4>Immune checkpoint inhibitors (ICIs) have revolutionized systemic anti-tumor treatments across different types of cancer. Nevertheless, predictive biomarkers regarding treatment response are not routinely established yet. Apart from T-lymphocytes, the humoral immunity of B-lymphocytes is studied to a substantially lesser extent in the respective setting. Thus, the aim of this study was to evaluate peripheral blood B-cell subtypes as potential predictors of ICI treatment response.<h4>Methods</h4>Thirty-nine cancer patients receiving ICI therapy were included into this prospective single-center cohort study. All had a first blood draw at the date before treatment initiation and a second at the time of first response evaluation (after 8-12 weeks). Seven different B-cell subt2022-01-01T00:00:00Z20222025-04-05T13:24:42.739Z2025-04-05T13:24:42.739ZS-EPMC90108713543236210.3389/fimmu.2022.840207